Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer

Tibor Szarvas, Bernhard B. Singer, Markus Becker, Frank Vom Dorp, Tobias Jäger, Attila Szendråi, Péter Riesz, I. Romics, Herbert Rübben, Süleyman Ergün

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

OBJECTIVE • To assess the presence of matrix metalloproteinase (MMP)-7 in urine samples of patients with bladder cancer and to investigate the correlation between MMP-7 urine concentration and clinicopathological variables. PATIENTS AND METHODS • The presence of MMP-7 in the urine of patients with bladder cancer was tested in 32 representative cases using immunoprecipitation followed by western blot analysis. • Urinary MMP-7 concentration levels were analyzed in 132 patients with bladder cancer and 96 controls using an enzyme-linked immunosorbent assay. RESULTS • MMP-7 levels did not differ significantly between patients with localized bladder cancer and controls (P= 0.174). On the other hand, we detected a fourfold, significantly elevated MMP-7 concentration in urine samples of patients with bladder cancer with regional or distant metastasis (P= 0.003). • Using a threshold value of 6.88 ng/ml, determined by receiver-operating characteristic curve analysis, a specificity of 82% and a sensitivity of 78% were observed. • Western blot analysis revealed that the 55-kDa tissue inhibitor of metalloproteinase 1 complexed MMP-7 is the dominant form of urinary matrilysin. CONCLUSIONS • MMP-7 is present in detectable amounts in the urine of patients with bladder cancer. Its concentrations are significantly elevated in patients with metastatic disease. • Determination of urinary matrilysin level could help to detect bladder cancer metastasis, and may therefore provide a more reliable prognosis and influence therapy decisions.

Original languageEnglish
Pages (from-to)1069-1073
Number of pages5
JournalBJU International
Volume107
Issue number7
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Matrix Metalloproteinase 7
Urinary Bladder Neoplasms
Neoplasm Metastasis
Urine
Western Blotting
Tissue Inhibitor of Metalloproteinase-1
Immunoprecipitation
ROC Curve
Enzyme-Linked Immunosorbent Assay

Keywords

  • bladder cancer
  • matrilysin
  • metastasis
  • MMP-7
  • prognosis
  • urine

ASJC Scopus subject areas

  • Urology

Cite this

Szarvas, T., Singer, B. B., Becker, M., Vom Dorp, F., Jäger, T., Szendråi, A., ... Ergün, S. (2011). Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer. BJU International, 107(7), 1069-1073. https://doi.org/10.1111/j.1464-410X.2010.09625.x

Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer. / Szarvas, Tibor; Singer, Bernhard B.; Becker, Markus; Vom Dorp, Frank; Jäger, Tobias; Szendråi, Attila; Riesz, Péter; Romics, I.; Rübben, Herbert; Ergün, Süleyman.

In: BJU International, Vol. 107, No. 7, 04.2011, p. 1069-1073.

Research output: Contribution to journalArticle

Szarvas, T, Singer, BB, Becker, M, Vom Dorp, F, Jäger, T, Szendråi, A, Riesz, P, Romics, I, Rübben, H & Ergün, S 2011, 'Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer', BJU International, vol. 107, no. 7, pp. 1069-1073. https://doi.org/10.1111/j.1464-410X.2010.09625.x
Szarvas, Tibor ; Singer, Bernhard B. ; Becker, Markus ; Vom Dorp, Frank ; Jäger, Tobias ; Szendråi, Attila ; Riesz, Péter ; Romics, I. ; Rübben, Herbert ; Ergün, Süleyman. / Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer. In: BJU International. 2011 ; Vol. 107, No. 7. pp. 1069-1073.
@article{07d05370eae54544b4895469c62b0322,
title = "Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer",
abstract = "OBJECTIVE • To assess the presence of matrix metalloproteinase (MMP)-7 in urine samples of patients with bladder cancer and to investigate the correlation between MMP-7 urine concentration and clinicopathological variables. PATIENTS AND METHODS • The presence of MMP-7 in the urine of patients with bladder cancer was tested in 32 representative cases using immunoprecipitation followed by western blot analysis. • Urinary MMP-7 concentration levels were analyzed in 132 patients with bladder cancer and 96 controls using an enzyme-linked immunosorbent assay. RESULTS • MMP-7 levels did not differ significantly between patients with localized bladder cancer and controls (P= 0.174). On the other hand, we detected a fourfold, significantly elevated MMP-7 concentration in urine samples of patients with bladder cancer with regional or distant metastasis (P= 0.003). • Using a threshold value of 6.88 ng/ml, determined by receiver-operating characteristic curve analysis, a specificity of 82{\%} and a sensitivity of 78{\%} were observed. • Western blot analysis revealed that the 55-kDa tissue inhibitor of metalloproteinase 1 complexed MMP-7 is the dominant form of urinary matrilysin. CONCLUSIONS • MMP-7 is present in detectable amounts in the urine of patients with bladder cancer. Its concentrations are significantly elevated in patients with metastatic disease. • Determination of urinary matrilysin level could help to detect bladder cancer metastasis, and may therefore provide a more reliable prognosis and influence therapy decisions.",
keywords = "bladder cancer, matrilysin, metastasis, MMP-7, prognosis, urine",
author = "Tibor Szarvas and Singer, {Bernhard B.} and Markus Becker and {Vom Dorp}, Frank and Tobias J{\"a}ger and Attila Szendr{\aa}i and P{\'e}ter Riesz and I. Romics and Herbert R{\"u}bben and S{\"u}leyman Erg{\"u}n",
year = "2011",
month = "4",
doi = "10.1111/j.1464-410X.2010.09625.x",
language = "English",
volume = "107",
pages = "1069--1073",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer

AU - Szarvas, Tibor

AU - Singer, Bernhard B.

AU - Becker, Markus

AU - Vom Dorp, Frank

AU - Jäger, Tobias

AU - Szendråi, Attila

AU - Riesz, Péter

AU - Romics, I.

AU - Rübben, Herbert

AU - Ergün, Süleyman

PY - 2011/4

Y1 - 2011/4

N2 - OBJECTIVE • To assess the presence of matrix metalloproteinase (MMP)-7 in urine samples of patients with bladder cancer and to investigate the correlation between MMP-7 urine concentration and clinicopathological variables. PATIENTS AND METHODS • The presence of MMP-7 in the urine of patients with bladder cancer was tested in 32 representative cases using immunoprecipitation followed by western blot analysis. • Urinary MMP-7 concentration levels were analyzed in 132 patients with bladder cancer and 96 controls using an enzyme-linked immunosorbent assay. RESULTS • MMP-7 levels did not differ significantly between patients with localized bladder cancer and controls (P= 0.174). On the other hand, we detected a fourfold, significantly elevated MMP-7 concentration in urine samples of patients with bladder cancer with regional or distant metastasis (P= 0.003). • Using a threshold value of 6.88 ng/ml, determined by receiver-operating characteristic curve analysis, a specificity of 82% and a sensitivity of 78% were observed. • Western blot analysis revealed that the 55-kDa tissue inhibitor of metalloproteinase 1 complexed MMP-7 is the dominant form of urinary matrilysin. CONCLUSIONS • MMP-7 is present in detectable amounts in the urine of patients with bladder cancer. Its concentrations are significantly elevated in patients with metastatic disease. • Determination of urinary matrilysin level could help to detect bladder cancer metastasis, and may therefore provide a more reliable prognosis and influence therapy decisions.

AB - OBJECTIVE • To assess the presence of matrix metalloproteinase (MMP)-7 in urine samples of patients with bladder cancer and to investigate the correlation between MMP-7 urine concentration and clinicopathological variables. PATIENTS AND METHODS • The presence of MMP-7 in the urine of patients with bladder cancer was tested in 32 representative cases using immunoprecipitation followed by western blot analysis. • Urinary MMP-7 concentration levels were analyzed in 132 patients with bladder cancer and 96 controls using an enzyme-linked immunosorbent assay. RESULTS • MMP-7 levels did not differ significantly between patients with localized bladder cancer and controls (P= 0.174). On the other hand, we detected a fourfold, significantly elevated MMP-7 concentration in urine samples of patients with bladder cancer with regional or distant metastasis (P= 0.003). • Using a threshold value of 6.88 ng/ml, determined by receiver-operating characteristic curve analysis, a specificity of 82% and a sensitivity of 78% were observed. • Western blot analysis revealed that the 55-kDa tissue inhibitor of metalloproteinase 1 complexed MMP-7 is the dominant form of urinary matrilysin. CONCLUSIONS • MMP-7 is present in detectable amounts in the urine of patients with bladder cancer. Its concentrations are significantly elevated in patients with metastatic disease. • Determination of urinary matrilysin level could help to detect bladder cancer metastasis, and may therefore provide a more reliable prognosis and influence therapy decisions.

KW - bladder cancer

KW - matrilysin

KW - metastasis

KW - MMP-7

KW - prognosis

KW - urine

UR - http://www.scopus.com/inward/record.url?scp=78549286948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78549286948&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2010.09625.x

DO - 10.1111/j.1464-410X.2010.09625.x

M3 - Article

VL - 107

SP - 1069

EP - 1073

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 7

ER -